On November 13, 2012 Topotarget reported that the company has entered into an exclusive license agreement with Oncology Venture ApS granting Oncology Venture global rights to the further clinical development of APO010 (Press release TopoTarget, NOV 13, 2012, View Source;messageId=651790 [SID:1234500427]).
APO010 is an anti-cancer drug comprising multimerised Fas ligand, which utilizes Topotarget’s proprietary Mega ligand technology (a non-core component of Topotarget’s IP assets). APO010 targets Fas receptors on the surface of cancer cells and induces cell death via apoptosis. APO010 has shown activity in otherwise drug-resistant cells.
Under the agreement, Oncology Venture will license all rights specific to APO010 which are covered by Topotarget’s issued and pending patents in Europe, the US, Canada, Japan, Australia, South Korea, and other territories. The agreement also grants Oncology Venture the right to sub-license.
No details of the terms of the agreement were disclosed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!